The Newsroom
NeOnc’s NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas (www.wallstreet-pr.com) –
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (Nasdaq: NTHI) is set up for a potential high impact catalyst day with what market observers are describing
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc’s Global Neuro-Oncology Strategy
International Regulatory Validation Has Preceded Several Recent FDA Success Stories, Though Significant Development Risks Remain Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) recently achieved
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
New Funding Structure Includes Redemption Rights, Ownership Limitations, and Conversion Floor as Investors Monitor Upcoming Clinical Updates Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (NASDAQ:NTHI)
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade
NeOnc Technologies Advances Novel Neuro-Oncology Therapies Targeting Glioblastoma and Other Hard-to-Treat Brain Cancers Houston, Texas (www.wallstreet-pr.com) – For years, artificial intelligence has dominated conversations surrounding
VENU Holding Corporation (NYSE: VENU): Napkin Math, Why It’s a Smarter 3-Year Play Than Nuclear, Robotics, Minerals, or AI
Senior Financial Editor Hey investors, Here’s a quick, back-of-the-envelope breakdown on why VENU Holdings inc. (NYSE:VENU), the upscale live music venue builder, could deliver explosive